NYSE · IQV
Healthcare · Medical - Diagnostics & Research
$261.75
Down-$0.63 (-0.24%)
Updated Aug 31, 2026, 9:35 AM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IQV closed at $261.75 after 20 trading sessions, up 12.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $260.55 | $262.82 | $258.08 | $261.75 | 1.84M |
| Aug 27, 2026 | $261.49 | $265.25 | $259.745 | $262.38 | 1.23M |
| Aug 26, 2026 | $254.91 | $262.51 | $253.155 | $261.51 | 1.27M |
| Aug 25, 2026 | $258.59 | $261.80 | $256.45 | $259.42 | 901.37K |
| Aug 24, 2026 | $256.81 | $261.88 | $255.79 | $260.24 | 1.11M |
| Aug 21, 2026 | $256.79 | $260.40 | $254.93 | $259.82 | 1.31M |
| Aug 20, 2026 | $246.87 | $260.30 | $246.87 | $256.05 | 1.79M |
| Aug 19, 2026 | $240.46 | $250.995 | $240.46 | $249.28 | 1.21M |
| Aug 18, 2026 | $244.36 | $246.02 | $239.98 | $240.03 | 1.1M |
| Aug 17, 2026 | $235.34 | $241.87 | $233.76 | $241.24 | 1.52M |
| Aug 14, 2026 | $240.55 | $243.00 | $235.865 | $236.66 | 905.61K |
| Aug 13, 2026 | $239.82 | $244.29 | $236.51 | $241.52 | 749.8K |
| Aug 12, 2026 | $239.80 | $243.76 | $238.0001 | $241.71 | 854.91K |
| Aug 11, 2026 | $241.47 | $245.30 | $240.72 | $243.84 | 1.08M |
| Aug 10, 2026 | $237.55 | $243.18 | $235.755 | $241.99 | 1.16M |
| Aug 7, 2026 | $232.41 | $238.78 | $230.495 | $238.70 | 1.05M |
| Aug 6, 2026 | $236.00 | $236.80 | $228.76 | $232.43 | 1.27M |
| Aug 5, 2026 | $233.49 | $238.22 | $231.34 | $236.05 | 1.56M |
| Aug 4, 2026 | $232.48 | $233.10 | $227.15 | $228.20 | 1.47M |
| Aug 3, 2026 | $237.17 | $238.49 | $230.83 | $233.36 | 1.64M |
The latest Smart Investors Daily articles mentioning IQV.
IQV research
Company profile and research snapshot.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | RBC Capital | Outperform | — |
| Jul 29, 2026 | TD Cowen | Buy | — |
| Jul 29, 2026 | Stifel | Buy | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
| Jul 29, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Mar 24, 2026
IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 9, 2026, TD Cowen upgraded its rating on IQVIA Holdings Inc. (NYSE:IQV) from Hold to Buy. Along with the rating upgrade, the firm also raised its price target on the stock from $174 to […]
Yahoo · Mar 23, 2026
What IQVIA Holdings’ Recent Performance Tells You IQVIA Holdings (IQV) has attracted attention after a period of weak share performance, including a return of about 26% decline year to date and 26% decline over the past 3 months. At a last close of US$166.07 and a market value near US$27.9b, the company combines sizeable scale with a mixed recent return profile, including a 0.3% gain over the past month but a 10.7% decline over the past year. See our latest analysis for IQVIA Holdings. The...
Yahoo · Mar 20, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Yahoo · Mar 18, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IQV.
